Three-year clinical results from the TAXUS V de novo trial:: Longterm safety and efficacy of the paclitaxel-eluting TAXUS stent in complex lesions

被引：0
|
作者：
Ellis, Stephen G. [1 ]
Cannon, Louis A. [2 ]
Mann, Tiff [3 ]
Greenberg, Joel D. [4 ]
Cambier, Patrick A. [5 ]
O'Shaughnessy, Charles D. [6 ]
DeMaio, Samuel [7 ]
Hall, Patrick [8 ]
Powers, Eric [9 ]
Friedman, Mark [10 ]
Stone, Gregg W. [11 ]
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[2] Cardiac & Vasc Ctr No Michigan, Petoskey, OH USA
[3] WakeMed, Raleigh, NC USA
[4] Florida Hosp, Orlando, FL USA
[5] Heart & Vasc Inst Florida, Clearwater, FL USA
[6] Elyria Mem Hosp, Elyria, OH USA
[7] S Austin Hosp, Austin, TX USA
[8] Sisters Char Providence Hosp, Columbia, SC USA
[9] Univ Virginia Cardiol, Charlottesville, VA USA
[10] Boston Sci Corp, Marlborough, MA USA
[11] Columbia Univ, Med Ctr, New York, NY 10027 USA
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2007年 / 100卷 / 8A期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：35L / 35L
页数：1
相关论文
共 50 条
  • [31] Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I)
    Grube, E
    Silber, S
    Hauptmann, KE
    Buellesfeld, L
    Mueller, R
    Lim, V
    Gerckens, U
    Russell, ME
    AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (01): : 79 - 82
  • [32] Impact of glycemic status on outcomes after paclitaxel-eluting stent implantation: Results from the TAXUS V study
    Powers, E
    Ellis, SG
    DeMaio, S
    Kimmelstiel, C
    Nesto, RW
    McNamara, R
    Satler, L
    Koglin, J
    Stone, GW
    AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (7A): : 177H - 178H
  • [33] Paclitaxel-eluting stent in complicated lesions or patient subsets: A subanalysis from the TAXUS II study
    Finci, L
    Silber, S
    Grube, E
    Belardi, J
    Ormiston, J
    Strauss, B
    Guagliumi, G
    Russell, M
    Colombo, A
    Colombo, A
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 46A - 46A
  • [34] Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial
    Ellis, Stephen G.
    O'Shaughnessy, Charles D.
    Martin, Steven L.
    Kent, Kenneth
    McGarrys, Thomas
    Turco, Mark A.
    Kereiakes, Dean J.
    Popma, Jeffrey J.
    Friedman, Mark
    Koglin, Joerg
    Stone, Gregg W.
    EUROPEAN HEART JOURNAL, 2008, 29 (13) : 1625 - 1634
  • [35] Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents Final 5-Year Analysis From the TAXUS Clinical Trial Program
    Stone, Gregg W.
    Ellis, Stephen G.
    Colombo, Antonio
    Grube, Eberhard
    Popma, Jeffrey J.
    Uchida, Takahiro
    Bleuit, Jill S.
    Dawkins, Keith D.
    Russell, Mary E.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (05) : 530 - 542
  • [36] The paclitaxel (TAXUS™)-eluting stent: A review of its use in the management of de novo coronary artery lesions
    Waugh J.
    Wagstaff A.J.
    American Journal of Cardiovascular Drugs, 2004, 4 (4) : 257 - 268
  • [37] A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions 12-Month Outcomes From the ENDEAVOR IV Trial
    Leon, Martin B.
    Mauri, Laura
    Popma, Jeffrey J.
    Cutlip, Donald E.
    Nikolsky, Eugenia
    O'Shaughnessy, Charles
    Overlie, Paul A.
    McLaurin, Brent T.
    Solomon, Stuart L.
    Douglas, John S., Jr.
    Ball, Michael W.
    Caputo, Ronald P.
    Jain, Ash
    Tolleson, Thaddeus R.
    Reen, Bernard M., III
    Kirtane, Ajay J.
    Fitzgerald, Peter J.
    Thompson, Kweli
    Kandzari, David E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (06) : 543 - 554
  • [38] TAXUS II 3-year clinical follow-up: Long-term safety and efficacy post polymer-based paclitaxel-eluting stent implantation for de novo coronary artery lesions
    Colombo, A
    Banning, A
    Silber, S
    Hauptmann, KE
    Drzewiecki, J
    Grube, E
    Wijatyk, A
    Russell, ME
    CIRCULATION, 2005, 112 (17) : U713 - U713
  • [39] 5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents Final Results From the SPIRIT III Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)
    Gada, Hemal
    Kirtane, Ajay J.
    Newman, William
    Sanz, Mark
    Hermiller, James B.
    Mahaffey, Kenneth W.
    Cutlip, Donald E.
    Sudhir, Krishnankutty
    Hou, Liming
    Koo, Kai
    Stone, Gregg W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2013, 6 (12) : 1263 - 1266
  • [40] Late Safety Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary, Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
    Leon, Martin B.
    Kandzari, David E.
    Eisenstein, Eric L.
    Anstrom, Kevin J.
    Mauri, Laura
    Cutlip, Donald E.
    Nikolsky, Eugenia
    O'Shaughnessy, Charles
    Overlie, Paul A.
    Kirtane, Ajay J.
    McLaurin, Brent T.
    Solomon, Stuart L.
    Douglas, John S., Jr.
    Popma, Jeffrey J.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (12) : 1208 - 1218
12345